Short Interest in Carisma Therapeutics, Inc. (NASDAQ:CARM) Decreases By 5.4%

Carisma Therapeutics, Inc. (NASDAQ:CARM) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 537,700 shares, a drop of 5.4% from the December 15th total of 568,400 shares. Based on an average daily trading volume, of 252,500 shares, the short-interest ratio is presently 2.1 days. Approximately 2.5% of the company’s stock are sold short.

Carisma Therapeutics Trading Down 3.5 %

Shares of CARM stock opened at $0.44 on Monday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. The company has a market capitalization of $18.40 million, a price-to-earnings ratio of -0.28 and a beta of 1.56. Carisma Therapeutics has a 52-week low of $0.38 and a 52-week high of $2.77. The company has a 50-day simple moving average of $0.63 and a two-hundred day simple moving average of $0.90.

Carisma Therapeutics (NASDAQ:CARM) last released its earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.31). The company had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. Research analysts anticipate that Carisma Therapeutics will post -1.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Barclays PLC boosted its holdings in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after buying an additional 549,290 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Carisma Therapeutics in the second quarter worth about $40,000. Finally, Wexford Capital LP raised its position in Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares during the period. Institutional investors own 44.27% of the company’s stock.

Analyst Ratings Changes

CARM has been the topic of a number of research reports. Baird R W downgraded Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Carisma Therapeutics in a research report on Monday, January 13th. HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th. Evercore ISI restated an “in-line” rating and set a $0.70 price objective (down previously from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. Finally, EF Hutton Acquisition Co. I raised shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Five analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $4.94.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.